Many life sciences contracts, including
intellectual property licensing agreements, development agreements
and supply agreements, contain force majeure clauses.
Depending upon the language of these clauses, the COVID-19 pandemic
may be an event that triggers these clauses and provides a defense
to nonperformance of the contract. Companies that are
experiencing difficulties complying with or enforcing compliance
with their contracts should carefully examine their contracts to
determine if a force majeure clause may excuse performance.
As COVID-191 continues to rapidly sweep the globe,
government agencies at all levels are being pressed to take
difficult measures to curb the spread of the virus. Such
measures have included restrictions on travel and congregation that
may create business disruption. For example, as of the end of
March, 2020, more than 35 states have shelter-in-place rules
covering all or part of the state.2 And, even in
states or localities that